Company Overview
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Why Investors Should Care
Revenue has grown at a 27.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $147.17M (+17.2% YoY); net profit $-408.35M.
- Trailing 12 Months Year-on-year growth — revenue +25.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 27.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 27.58% |
| 1 Year: | 25.70% |
Stock Price Performance
| 1 Year: | +273.93% |
| 6 Months: | +150.86% |
| 3 Months: | +87.29% |
| 1 Month: | +17.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 27.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GRAL GRAIL, Inc. R2KR3KPHARMA | 127.06 | -13.11 | $5.68B | 0.00% | -18.79% | -16.12% | 27.58% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Apr 2023 | Jun 2023 | Jul 2023 | Oct 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 22.41M | - | 20.72M | 26.72M | 31.97M | 28.65M | 31.84M | 35.54M | 36.19M | 40.78M | 44.69M |
| Operating Income | - | - | -204.37M | - | -912.39M | -227.42M | -1.64B | -183.51M | -153.61M | -158.85M | -125.29M | -135.76M | -173.78M |
| Net Income | -193.67M | -193.67M | -193.04M | -193.04M | -891.45M | -218.91M | -1.59B | -125.69M | -106.21M | -113.98M | -88.98M | -93.19M | -110.25M |
| Diluted EPS | - | - | -6.22 | - | -28.71 | -7.05 | -51.06 | -3.94 | -3.10 | -3.18 | -2.46 | -2.29 | -2.56 |
| R&D Expense | - | - | - | - | - | 101.62M | 94.20M | 78.23M | 53.62M | 46.63M | 48.65M | 48.02M | 47.43M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.55M | 55.55M | 93.11M | 125.59M | 147.17M |
| Cost of Revenue | 172.00M | - | 188.72M | 203.62M | 209.75M |
| Gross Profit | -116.45M | - | -95.61M | -78.02M | -62.57M |
| Operating Expenses | 626.01M | - | 701.30M | 690.20M | 471.59M |
| Operating Income | -742.46M | -5.44B | -796.92M | -768.22M | -534.16M |
| EBITDA | -587.70M | - | -638.22M | -610.17M | -377.82M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -5.44B | - | -1.51B | -2.16B | -534.50M |
| Tax Provision | -42.29M | - | -41.95M | -135.36M | -126.15M |
| Net Income | -5.40B | -5.40B | -1.47B | -2.03B | -408.35M |
| Diluted EPS | -173.89 | -173.89 | -47.21 | -63.54 | -11.11 |
| R&D Expense | - | 329.58M | 338.75M | 322.38M | 195.79M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 3.91B | 2.98B | 2.92B |
| Total Equity | - | - | 2.50B | 2.58B |
| Cash & Equivalents | 241.60M | 97.29M | 214.23M | 249.73M |
| Total Liabilities | - | 267.63M | 479.90M | 344.15M |
| Current Liabilities | - | 163.61M | 76.92M | 79.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -561.31M | -595.80M | -577.16M | -299.01M |
| Investing Cash Flow | -22.86M | -12.89M | -551.01M | -85.05M |
| Financing Cash Flow | 604.82M | 463.77M | 1.24B | 423.32M |
| Capital Expenditure | -22.86M | -12.89M | -5.21M | -909.00K |
| Free Cash Flow | -584.17M | -608.69M | -582.36M | -299.92M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | -209.6% | - | -102.7% | -62.1% | -42.5% |
| Operating Margin % | -1,336.6% | -9,798.2% | -855.9% | -611.7% | -363.0% |
| Net Margin % | -9,719.3% | -9,719.3% | -1,574.2% | -1,613.9% | -277.5% |
| ROE % | - | - | - | -81.0% | -15.8% |
| ROCE % | - | - | -21.2% | -26.4% | -18.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Farallon Capital Management LLC | 9.32% | 4.16M | $585.04M |
| 2 | Baker Bros. Advisors, LP | 9.02% | 4.03M | $566.34M |
| 3 | Blackrock Inc. | 8.01% | 3.58M | $502.87M |
| 4 | State Street Corporation | 5.34% | 2.39M | $335.36M |
| 5 | Primecap Management Company | 4.88% | 2.18M | $306.48M |
| 6 | Sessa Capital IM, L.P. | 4.56% | 2.04M | $286.43M |
| 7 | Deep Track Capital, Lp | 4.11% | 1.83M | $257.96M |
| 8 | Vanguard Capital Management LLC | 3.67% | 1.64M | $230.71M |
| 9 | Morgan Stanley | 3.27% | 1.46M | $205.55M |
| 10 | Arbiter Partners Capital Management LLC | 2.32% | 1.03M | $145.40M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GRAL
GRAL Stock Slumps 48% After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxNVzlWR0JtbmVWcjZJQV80M0UzRjNoZjhZdktnVEUxWlVDUzNRM0R4bUJsZUlCU3R2SVUwT1haSjVjZGRTdEo3a2lNWVRyNjhLREhxR1F6UUI1S3YzWmN0US1mZ2otaVZDVU8yYXZRaS13dnlXNldMTEZOV1R5LW14ME9ISTVNV1BGS2Z4N2…
GRAL Jan 2027 240.000 call (GRAL270115C00240000) interactive stock chart - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBRNndWRkdtekVUbWZQSlBtN0RBWFVZS1k0cklObjF5SllyYjZ4YTRkWEFLV2h4amxFYk42NG1LWVlkRVRuZkFTcFdHVkdLcDgyN0h3SHI2N1BQRmNVenBaRGtlZlhmWXpTOW1janhR?oc=5" target="_blank">GRAL Jan 2027 240.0…
This Stock, Up Almost 70%, May Have Found Cancer's Holy 'Grail' - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNWHdZRVlWR0wxVnB4cllFcWZGdFFqYlFtQldMQkF2enQtNTJpMkFsaDVyQjJ0MWdFbzlHck5TSmZlOWd1WVJYcWVjS0JPS3RRSk9uUVdOTHBSMHFiNzBJRzVQWk1KbVVVYnYtNzJhWFMtaFRNVVhBNXFHOFRVUGR6QUdKOC1RZU5SM21zOF…
GRAIL Reports Second Quarter 2026 Financial Results - GRAIL
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPSlhCLTJiWTJuOFJiUDllTzZ6a1k5cDl4NGp4Wm0yNGtyM0p6UXZDR2JyZFFjYWdVOFVITVRGYjFyWjdHaXlyejR4QzhVcnc5NzlNcTlwN2ZmcHBsbXZWaV9NNXpPYnQ0UXVkeXdzMUpuaGd1ZDVGTl9FQ0U0eG5xMU5Dc09pQjR6NHZlUm…
GRAL Nov 2026 170.000 put (GRAL261120P00170000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9HbHpCWi01TlRHajNPODR6SFZZZTlpWDBGYVhtWi1GWjIwU1UwWmQ3X3U2MjVKdVVXNl81Nm1IbUNuaEo4TFBoR0c1OW5PWEluUkJNVEFjSkNzMldfeVZpTGNIZnhsQQ?oc=5" target="_blank">GRAL Nov 2026 170.000 put (GR…
GRAL Jan 2028 180.000 put (GRAL280121P00180000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5QcTM0aERFbmpZbzU3NHZsRW5taFBkZUEydmZxZlg3ZVBGeGM5SzFaSWhXLWZRcFZCRnpGcW9GWEhUZVU4bU9PalJzTlcwVG5CRU5LR21SQUVMTXo4YkNaemxOVEktdw?oc=5" target="_blank">GRAL Jan 2028 180.000 put (GR…
GRAL — Frequently Asked Questions
What is the current share price of GRAIL, Inc. (GRAL)?
As of 2026-10-22 16:30 PDT, GRAIL, Inc. (GRAL) trades at $127.06 on NasdaqGS. Its 52-week range is $31.42 to $154.08.
What is the market capitalisation of GRAL?
GRAIL, Inc. (GRAL) has a market capitalisation of $5.68B on NasdaqGS.
What is the P/E ratio of GRAL?
GRAL trades at a trailing price-to-earnings (P/E) ratio of -13.11. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 1.42.
What is the return on equity (ROE) of GRAL?
GRAL has a return on equity (ROE) of -16.12%. Its return on capital employed (ROCE) is -18.79%.
Is GRAL a good stock to buy?
This page provides a data-driven analysis of GRAIL, Inc. (GRAL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.